The “Yin and Yang” of natural compounds in anticancer therapy of triple-negative breast cancers

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Among the different types of breast cancers, triple-negative breast cancers (TNBCs) are highly aggressive, do not respond to conventional hormonal/human epidermal growth factor receptor 2 (HER2)-targeted interventions due to the lack of the respective receptor targets, have chances of early recurrence, metastasize, tend to be more invasive in nature, and develop drug resistance. The global burden of TNBCs is increasing regardless of the number of cytotoxic drugs being introduced into the market each year as they have only moderate efficacy and/or unforeseen side effects. Therefore, the demand for more efficient therapeutic interventions, with reduced side effects, for the treatment of TNBCs is rising. While some plant metabolites/derivatives actually induce the risk of cancers, many plant-derived active principles have gained attention as efficient anticancer agents against TNBCs, with fewer adverse side effects. Here we discuss the possible oncogenic molecular pathways in TNBCs and how the purified plant-derived natural compounds specifically target and modulate the genes and/or proteins involved in these aberrant pathways to exhibit their anticancer potential. We have linked the anticancer potential of plant-derived natural compounds (luteolin, chalcones, piperine, deguelin, quercetin, rutin, fisetin, curcumin, resveratrol, and others) to their ability to target multiple dysregulated signaling pathways (such as the Wnt/β-catenin, Notch, NF-κB, PI3K/Akt/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Hedgehog) leading to suppression of cell growth, proliferation, migration, inflammation, angiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, and activation of apoptosis in TNBCs. Plant-derived compounds in combination with classical chemotherapeutic agents were more efficient in the treatment of TNBCs, possibly with lesser side effects.

Original languageEnglish
Article number346
JournalCancers
Volume10
Issue number10
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Yin-Yang
Triple Negative Breast Neoplasms
Phytochemicals
piperine
Therapeutics
Chalcones
Luteolin
Catenins
Rutin
Curcumin
Epithelial-Mesenchymal Transition
Hedgehogs
Quercetin
Sirolimus
Mitogen-Activated Protein Kinases
Phosphatidylinositol 3-Kinases
Drug Resistance
Antineoplastic Agents
Cell Proliferation
Apoptosis

Keywords

  • Anticancer therapy
  • Apoptosis
  • Chemotherapy
  • Natural compounds
  • Signaling pathways
  • Triple-negative breast cancers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The “Yin and Yang” of natural compounds in anticancer therapy of triple-negative breast cancers. / Varghese, Elizabeth; Mathews Samuel, Samson; Abotaleb, Mariam; Cheema, Sohaila; Mamtani, Ravinder; Busselberg, Dietrich.

In: Cancers, Vol. 10, No. 10, 346, 01.10.2018.

Research output: Contribution to journalReview article

@article{e820fec26b9444a1a9fb616fb2c55f98,
title = "The “Yin and Yang” of natural compounds in anticancer therapy of triple-negative breast cancers",
abstract = "Among the different types of breast cancers, triple-negative breast cancers (TNBCs) are highly aggressive, do not respond to conventional hormonal/human epidermal growth factor receptor 2 (HER2)-targeted interventions due to the lack of the respective receptor targets, have chances of early recurrence, metastasize, tend to be more invasive in nature, and develop drug resistance. The global burden of TNBCs is increasing regardless of the number of cytotoxic drugs being introduced into the market each year as they have only moderate efficacy and/or unforeseen side effects. Therefore, the demand for more efficient therapeutic interventions, with reduced side effects, for the treatment of TNBCs is rising. While some plant metabolites/derivatives actually induce the risk of cancers, many plant-derived active principles have gained attention as efficient anticancer agents against TNBCs, with fewer adverse side effects. Here we discuss the possible oncogenic molecular pathways in TNBCs and how the purified plant-derived natural compounds specifically target and modulate the genes and/or proteins involved in these aberrant pathways to exhibit their anticancer potential. We have linked the anticancer potential of plant-derived natural compounds (luteolin, chalcones, piperine, deguelin, quercetin, rutin, fisetin, curcumin, resveratrol, and others) to their ability to target multiple dysregulated signaling pathways (such as the Wnt/β-catenin, Notch, NF-κB, PI3K/Akt/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Hedgehog) leading to suppression of cell growth, proliferation, migration, inflammation, angiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, and activation of apoptosis in TNBCs. Plant-derived compounds in combination with classical chemotherapeutic agents were more efficient in the treatment of TNBCs, possibly with lesser side effects.",
keywords = "Anticancer therapy, Apoptosis, Chemotherapy, Natural compounds, Signaling pathways, Triple-negative breast cancers",
author = "Elizabeth Varghese and {Mathews Samuel}, Samson and Mariam Abotaleb and Sohaila Cheema and Ravinder Mamtani and Dietrich Busselberg",
year = "2018",
month = "10",
day = "1",
doi = "10.3390/cancers10100346",
language = "English",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - The “Yin and Yang” of natural compounds in anticancer therapy of triple-negative breast cancers

AU - Varghese, Elizabeth

AU - Mathews Samuel, Samson

AU - Abotaleb, Mariam

AU - Cheema, Sohaila

AU - Mamtani, Ravinder

AU - Busselberg, Dietrich

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Among the different types of breast cancers, triple-negative breast cancers (TNBCs) are highly aggressive, do not respond to conventional hormonal/human epidermal growth factor receptor 2 (HER2)-targeted interventions due to the lack of the respective receptor targets, have chances of early recurrence, metastasize, tend to be more invasive in nature, and develop drug resistance. The global burden of TNBCs is increasing regardless of the number of cytotoxic drugs being introduced into the market each year as they have only moderate efficacy and/or unforeseen side effects. Therefore, the demand for more efficient therapeutic interventions, with reduced side effects, for the treatment of TNBCs is rising. While some plant metabolites/derivatives actually induce the risk of cancers, many plant-derived active principles have gained attention as efficient anticancer agents against TNBCs, with fewer adverse side effects. Here we discuss the possible oncogenic molecular pathways in TNBCs and how the purified plant-derived natural compounds specifically target and modulate the genes and/or proteins involved in these aberrant pathways to exhibit their anticancer potential. We have linked the anticancer potential of plant-derived natural compounds (luteolin, chalcones, piperine, deguelin, quercetin, rutin, fisetin, curcumin, resveratrol, and others) to their ability to target multiple dysregulated signaling pathways (such as the Wnt/β-catenin, Notch, NF-κB, PI3K/Akt/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Hedgehog) leading to suppression of cell growth, proliferation, migration, inflammation, angiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, and activation of apoptosis in TNBCs. Plant-derived compounds in combination with classical chemotherapeutic agents were more efficient in the treatment of TNBCs, possibly with lesser side effects.

AB - Among the different types of breast cancers, triple-negative breast cancers (TNBCs) are highly aggressive, do not respond to conventional hormonal/human epidermal growth factor receptor 2 (HER2)-targeted interventions due to the lack of the respective receptor targets, have chances of early recurrence, metastasize, tend to be more invasive in nature, and develop drug resistance. The global burden of TNBCs is increasing regardless of the number of cytotoxic drugs being introduced into the market each year as they have only moderate efficacy and/or unforeseen side effects. Therefore, the demand for more efficient therapeutic interventions, with reduced side effects, for the treatment of TNBCs is rising. While some plant metabolites/derivatives actually induce the risk of cancers, many plant-derived active principles have gained attention as efficient anticancer agents against TNBCs, with fewer adverse side effects. Here we discuss the possible oncogenic molecular pathways in TNBCs and how the purified plant-derived natural compounds specifically target and modulate the genes and/or proteins involved in these aberrant pathways to exhibit their anticancer potential. We have linked the anticancer potential of plant-derived natural compounds (luteolin, chalcones, piperine, deguelin, quercetin, rutin, fisetin, curcumin, resveratrol, and others) to their ability to target multiple dysregulated signaling pathways (such as the Wnt/β-catenin, Notch, NF-κB, PI3K/Akt/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Hedgehog) leading to suppression of cell growth, proliferation, migration, inflammation, angiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, and activation of apoptosis in TNBCs. Plant-derived compounds in combination with classical chemotherapeutic agents were more efficient in the treatment of TNBCs, possibly with lesser side effects.

KW - Anticancer therapy

KW - Apoptosis

KW - Chemotherapy

KW - Natural compounds

KW - Signaling pathways

KW - Triple-negative breast cancers

UR - http://www.scopus.com/inward/record.url?scp=85054520974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054520974&partnerID=8YFLogxK

U2 - 10.3390/cancers10100346

DO - 10.3390/cancers10100346

M3 - Review article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 346

ER -